Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding zomedica pharmaceuticals corp is ‘ strong sell ‘.
Will ZOM recover?
ZOM stock will likely struggle to recover in price over the next few months It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Is ZOM stock a buy?
Zomedica Corp (nyse american:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20 The median estimate represents a +358.19% increase from the last price of 0.26.
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by ” changes at our current distributor that we believe have impacted its ability to market our products effectively” Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Is Zomedica a good long term investment?
Moreover, during the nine months that ended on Sept. 30, 2021, Zomedica reported $52,331 of revenue and a net earnings loss of $15.1 million. Clearly, its current financial performance won’t be sustainable for the long-term.
Is Zomedica being shorted?
What is Zomedica’s current short interest? Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 101,490,000 shares of ZOM short. 10.52% of Zomedica’s shares are currently sold short.
Is TherapeuticsMD a good stock to buy?
TherapeuticsMD has received a consensus rating of Hold The company’s average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
What is the future of Zomedica stock?
If you are looking for stocks with good return, Zomedica Corp stock can be a bad, high-risk 1-year investment option Zomedica Corp real time quote is equal to 0.220 USD at 2022-06-30, but your current investment may be devalued in the future.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Does Zomedica have potential?
This diagnostics tool looks to disrupt a global veterinary diagnostic services market that is large and growing. Estimates are that this market will grow from an estimated valuation of $2.5 billion in 2021 to a projected value of $3.9 billion in 2026 That’s some decent growth.
Does Zom reverse split?
Despite now generating revenue from the sale of its Truforma diagnostics system, Zomedica is valued at nearly 70 times Wall Street’s projected sales for 2023. It’s also nowhere near profitability. It’s a strong candidate to enact a reverse split sometime over the next 12 to 18 months.
Is Sundial growers a buy?
Following the Q3 earnings report, Sundial shares experienced a strong rally. However, even though SNDL is worth just over 50 cents and is under pressure to pass the $1-per-share level to remain in compliance with Nasdaq, here are three reasons why buying the stock ahead of earnings could be a good deal.